On September 30, 2021 A global leader in the development of cancer related cannabinoid-based medicine and a pioneer in the development of psychedelic inspired medicine, reported that it has updated its corporate image with a new logo and a new website (Press release, Cannabics Pharmaceuticals, SEP 30, 2021, View Source [SID1234590557]). In addition, the company announced that a new corporate presentation is now available on its new website.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

These updates more fully reflect the company’s strategic shift from a pre-clinical stage company towards now becoming a clinical stage development corporation focused primarily on FDA regulatory compliance.

The updated site, www.cannabics.com, provides current details on each of the company’s drug candidates and their corresponding clinical path. As always, the site offers current news and investor information, including press releases, SEC filings and the newly updated company presentation featuring the latest on Cannabics development.